473416-74-9

Upstream product

• 147460-41-1 2-bromo-5-fluorophenol 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 74-88-4 methyl iodide 

Downstream Products

• 850363-67-6 5-bromo-4-methoxy-1H-indazole 
• 473416-75-0 benzo[b]furan-2-yl-(3-bromo-6-fluoro-2-methoxy-phenyl)-methanol 
• 1009094-86-3 C₁₅H₁₇ClINO₅ 
• 1009092-79-8 C₂₁H₃₁BrFNO₅Si 
• 1009093-37-1 C₂₁H₃₁ClINO₅Si 
• 1009092-80-1 C₂₅H₃₆BrFN₂O₅ 
• 1009093-38-2 C₂₅H₃₆ClIN₂O₅ 
• 1009092-87-8 C₂₅H₃₅BrFN₅O₄ 
• 1009094-75-0 C₃₂H₄₂FN₃O₇ 
• 1009093-39-3 C₃₄H₄₆ClN₃O₇ 
• 1009094-76-1 C₃₂H₄₂ClN₃O₇ 
• 1009092-81-2 C₃₄H₄₆FN₃O₇ 
• 1009092-88-9 C₃₄H₄₅FN₆O₆ 
• 1009093-33-7 C₄₂H₆₄ClN₅O₆ 

Relevant academic research and scientific papers

Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents

Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Synthesis method of 3-bromo-6-fluoro-2-methoxybenzaldehyde

The invention belongs to the field of organic synthesis, and discloses a synthesis method of 3-bromo-6-fluoro-2-methoxybenzaldehyde. The synthesis method provided by the invention comprises the following steps: dissolving paraformaldehyde, magnesium chlor

BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS

The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS

The present invention relates to novel indazole derivatives (I) having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.

NOVEL 1H-INDAZOLE COMPOUND

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C3-C8 cycloalkyl group, a C6-C14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.